QUAZAR: Should maintenance with CC-486 become standard of care following induction chemotherapy?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Andrew Wei, The Alfred Hospital, Victoria, AU about the results of the phase III QUAZAR AML-001 study. The QUAZAR study investigated the use of CC-486 as maintenance therapy in patients with acute myeloid leukemia (AML) who are in first remission following induction chemotherapy (with or without consolidation).

CC-486 is an orally administered hypomethylating agent which, since it can be given for longer per-cycle, has a longer duration of exposure than previously investigated agents. Dr Wei highlights that this is the first study to show a clinical benefit of maintenance therapy in patients with AML in first remission and anticipates this will lead to a change in the current standard of care treatment.